Non-alcoholic steatohepatitis (NASH), a cause of cirrhosis and hepatocellular carcinoma, is
characterized by fatty infiltration of the liver, inflammation, hepatocellular damage and …

Together with the global rise in obesity and metabolic syndrome, the prevalence of
individuals who suffer from nonalcoholic fatty liver disease (NAFLD) has risen dramatically …

Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome.
The prevalence of non-alcoholic fatty liver disease is around 20–30%, and with a rapid …

Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …

Non-alcoholic fatty liver disease (NAFLD) is currently the world's most common liver
disease, estimated to affect up to one-fourth of the population. Hallmarked by hepatic …

Non-alcoholic fatty liver disease (NAFLD) represents a wide spectrum of diseases, ranging
from simple fatty liver (hepatic steatosis) through steatosis with inflammation and necrosis to …

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and is
associated with significant morbidity and mortality worldwide, with a high incidence in …

Objective Aberrant ketogenesis is correlated with the degree of steatosis in non-alcoholic
fatty liver disease (NAFLD) patients, and an inborn error of ketogenesis (mitochondrial HMG …

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing
challenge in terms of prevention and treatment. Despite its high prevalence, only a small …

Non-alcoholic steatohepatitis (NASH) is considered the advanced stage of non-alcoholic
fatty liver disease (NAFLD). It is characterized by liver steatosis, inflammation and different …